Abatacept in the treatment of polyarticular JIA: Development, clinical utility, and place in therapy

Drug Design, Development and Therapy

Volumn , Issue 5, 2011, Pages 61-70

  Goldzweig, Ofra ^a   Hashkes, Philip J ^b,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Abatacept; Juvenile idiopathic arthritis; Treatment

Indexed keywords

ABATACEPT; ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT;

ABNORMAL LABORATORY RESULT; ARTHRALGIA; ARTHRITIS; BACTERIAL MENINGITIS; BENIGN TUMOR; COUGHING; DAILY LIFE ACTIVITY; DENGUE; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; ERYSIPELAS; FEVER; FOOT MALFORMATION; GASTROENTERITIS; HEADACHE; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; NAUSEA; NEOPLASM; PAIN ASSESSMENT; PROTEIN BLOOD LEVEL; PYELONEPHRITIS; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SLEEP PATTERN; T LYMPHOCYTE ACTIVATION; UPPER RESPIRATORY TRACT INFECTION; UVEITIS; CHILD; DRUG ANTAGONISM; DRUG COMBINATION; DRUG DESIGN; IMMUNOLOGY; PATHOPHYSIOLOGY; T LYMPHOCYTE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; DRUG DESIGN; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOCONJUGATES; METHOTREXATE; QUALITY OF LIFE; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952945682     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S16489     Document Type: Review

References (41)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369(9563):767-778.
2. Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: Outcome and treatment for the 1990s. Rheum Dis Clin North Am. 1991;17(4): 891-905.
3. Packham JC, Hall MA, Pimm TJ. Long-term follow-up of 246 adults with JIA: Predictive factors for mood and pain. Rheumatology (Oxford). 2002;41(12):1444-1449.
4. Minden K. Adult outcomes of patients with JIA. Horm Res. 2009; 72 Suppl 1:20-25.
5. Ruperto N, Levinson JE, Ravelli A, et al. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J Rheumatol. 1997;24(5):945-951.
6. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of JIA. Arthritis Rheum. 2005; 52(11):3554-3562.
7. Hashkes PJ, Laxer RM. Medical treatment of JIA. JAMA. 2005; 294(13):1671-1684.
8. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med. 1992;326(16):1043-1049.
9. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with JIA who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004;50(7):2191-2201.
10. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342(11):763-769.
11. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo- controlled trial of infliximab plus methotrexate for the treatment of polyarticularcourse juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9): 3096-3106.
12. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008; 359(8):810-820.
13. Ringold S, Seidel KD, Koepsell TD, Wallace CA. Inactive disease in polyarticular JIA: Current patterns and associations. Rheumatology (Oxford). 2009;48(8):972-977.
14. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496-1504.
15. Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for JIA. Nat Rev Rheumatol. 2010;6(10):561-571.
16. Macaubas C, Nguyen K, Milojevic D, Park JL, Mellins ED. Oligoarticular and polyarticular JIA: Epidemiology and pathogenesis. Nat Rev Rheumatol. 2009;5(11):616-626.
17. Nistala K, Wedderburn LR. Th17 and regulatory T cells: Rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology (Oxford). 2009;48(6):602-606.
18. Prakken BJ, Albani S. Using biology of disease to understand and guide therapy of JIA. Best Pract Res Clin Rheumatol. 2009;23(5): 599-608.
19. Hervey PS, Keam SJ. Abatacept. BioDrugs. 2006;20(1):53-61.
20. Goeb V, Buch MH, Vital EM, Emery P. Costimulation blockade in rheumatic diseases: Where we are? Curr Opin Rheumatol. 2009; 21(3):244-250.
21. Graca L. CTLA4Ig and the therapeutic potential of T cell co-stimulation blockade. Acta Reumatol Port. 2008;33(3):267-276. [Portuguese].
22. Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008; 67(4):547-554.
23. Orencia®[Package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Aug 2009.
24. Bruce SP, Boyce EG. Update on abatacept: A selective costimulation modulator for rheumatoid arthritis. Ann Pharmacother. 2007; 41(7):1153-1162.
25. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with JIA: A randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383-391.
26. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202-1209.
27. Ruperto N, Lovell DJ, Quartier P, et al; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010; 62(6):1792-1802.
28. Ruperto N, Lovell DJ, Li T, et al. Abatacept improves health-related quality of life, pain, sleep quality and daily participation in subjects with JIA. Arthritis Care Res (Hoboken). 2010;62(11):1542-1551.
29. Ruperto N, Ravelli A, Pistorio A, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol. 2001;19(4 Suppl 23):S1-S9.
30. Durmoqicz EL. Pediatric focused safety review. FDA [online]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ PediatricAdvisoryCommittee/ ucm193143.pdf. Accessed 2010 Dec 21.
31. Kuemmerle-Deschner JB, Benseler S. Abatacept in difficult-to-treat JIA. Biologics. 2008;2(4):865-874.
32. Ungar WJ, Costa V, Hancock-Howard R, Feldman BM, Laxer RM. Cost-effectiveness of biologics in polyarticular-course JIA patients unresponsive to disease modifying anti-rheumatic drugs. Arthritis Care Res (Hoboken).2011;63(1):111-119.
33. Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory JIA-related uveitis. Arthritis Care Res (Hoboken). 2010;62(6):821-825.
34. Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I. Abatacept: A potential therapy in refractory cases of JIA-associated uveitis. Graefes Arch Clin Exp Ophthalmol. Oct 5 2010. [Epub ahead of print].
35. Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: A clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010;69(3):510-516.
36. Ravelli A, Ioseliani M, Norambuena X, et al. Adapted versions of the Sharp/ van der Heijde score are reliable and valid for assessment of radiographic progression in JIA. Arthritis Rheum. 2007;56(9): 3087-3095.
37. Keystone EC, Kremer JM, Russell AS, et al. Switching patients with rheumatoid arthritis (RA) from intravenous (IV) to subcutaneous (SC) abatacept is well tolerated and sustains previously established efficacy [Abstract]. Arthritis Rheum. 2010;62(10 Suppl):S176
38. Hinks A, Worthington J, Thomson W. The association of PTPN22 with rheumatoid arthritis and JIA. Rheumatology (Oxford). 2006; 45(4):365-368.
39. Lee YH, Rho YH, Choi SJ, et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases - a meta-analysis. Rheumatology (Oxford). 2007;46(1):49-56.
40. Thompson SD, Sudman M, Ramos PS, et al. The susceptibility loci JIA shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1. Arthritis Rheum. 2010;62(11):3265-3276.
41. Gregersen PK, Lee HS, Batliwalla F, Begovich AB. PTPN22: Setting thresholds for autoimmunity. Semin Immunol. 2006;18(4):214-223.